SCHEDULE: Ewon Comfortech Discloses 10.9% Stake in Liminatus Pharma

Ewon Comfortech Co., Ltd. has reported beneficial ownership of 5,500,000 shares, representing 10.9% of Liminatus Pharma, Inc.'s common stock, as of June 24, 2026.

Summary

• Ewon Comfortech Co., Ltd. has filed a Schedule 13G, indicating it beneficially owns 5,500,000 shares of Liminatus Pharma, Inc. common stock.
• This holding represents 10.9% of the total outstanding shares of Liminatus Pharma, Inc.
• The filing is an amendment (Amendment No. 1) and the event date requiring the filing was June 24, 2026.
• Ewon Comfortech Co., Ltd. has sole voting power over 1,126,397 shares and sole dispositive power over 5,500,000 shares.
• The company is organized in the Republic of Korea.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on an existing ownership stake rather than providing new operational or financial performance data for Liminatus Pharma, Inc.

Positives

• Ewon Comfortech Co., Ltd. has acquired a significant stake (10.9%) in Liminatus Pharma, Inc., which could indicate confidence in the company's future prospects.
• The reporting person has sole dispositive power over the entire 5,500,000 shares, suggesting clear control over these holdings.

Risks

• The filing does not explicitly state the purpose of Ewon Comfortech's investment, leaving potential strategic intentions open to interpretation.
• A significant stake held by an external entity could lead to future activist investor actions or influence on corporate strategy, which may not align with current management's plans.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Liminatus Pharma, Inc. It solely reports on the ownership stake of Ewon Comfortech Co., Ltd.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant stakeholders acquiring substantial positions in publicly traded companies. This filing indicates Ewon Comfortech Co., Ltd. has become a notable shareholder in Liminatus Pharma, Inc., a development that investors will monitor for potential strategic implications within the pharmaceutical sector.

Stakeholder Impact

• Shareholders: The acquisition of a significant stake by Ewon Comfortech Co., Ltd. may influence share price volatility and future corporate strategy, impacting existing shareholders' investment value.
• Management of Liminatus Pharma, Inc.: May need to consider the influence of a large shareholder with sole dispositive power over a substantial portion of the company's stock.
• Potential Investors: This filing provides information about a significant shareholder, which may be a factor in their investment decisions.

Next Steps

• Investors will likely monitor Ewon Comfortech Co., Ltd.'s future actions regarding its stake in Liminatus Pharma, Inc.
• Further filings may be required if Ewon Comfortech's ownership percentage changes significantly.

Key Dates

Keywords

Schedule 13G, Liminatus Pharma, Ewon Comfortech, Beneficial Ownership, Common Stock, SEC Filing, Investment, Shareholder